Oral nonsteroidal anti-androgen

Ligand Pharmaceuticals has patents filed for the manufacture and therapeutic use of certain compounds occupying several stated chemical structures, which are intended for use as selective androgen receptor modulators. The patent is filed under the following designations: US8519158 B2, US8865918, US9359285, US20070254875, US20140005186, US20150099720, and WO2005090282A1. The patents will expire on March 12, 2025. These patents effectively protect any future capitalization upon VK5211 in the market by Viking and Ligand through their licensing agreement. [9]

Oral nonsteroidal anti-androgen

oral nonsteroidal anti-androgen

Media:

oral nonsteroidal anti-androgenoral nonsteroidal anti-androgenoral nonsteroidal anti-androgenoral nonsteroidal anti-androgenoral nonsteroidal anti-androgen